Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 1
2003 1
2004 2
2005 7
2006 7
2007 16
2008 18
2009 10
2010 18
2011 20
2012 20
2013 18
2014 11
2015 13
2016 29
2017 43
2018 29
2019 29
2020 27
2021 20
2022 23
2023 17
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

320 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.
Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves WI, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, Lin Y, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Muchtar E, et al. Among authors: hayman sr. Mayo Clin Proc. 2021 Jun;96(6):1546-1577. doi: 10.1016/j.mayocp.2021.03.012. Mayo Clin Proc. 2021. PMID: 34088417 Review.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Kumar S, et al. Among authors: hayman sr. J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724. Epub 2012 Feb 13. J Clin Oncol. 2012. PMID: 22331953 Free PMC article.
Amyloidosis.
Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Gertz MA, et al. Among authors: hayman sr. Best Pract Res Clin Haematol. 2005;18(4):709-27. doi: 10.1016/j.beha.2005.01.030. Best Pract Res Clin Haematol. 2005. PMID: 16026746 Review.
Conditional survival in multiple myeloma and impact of prognostic factors over time.
Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Hwa YL, Lin Y, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Abdallah NH, et al. Among authors: hayman sr. Blood Cancer J. 2023 May 15;13(1):78. doi: 10.1038/s41408-023-00852-4. Blood Cancer J. 2023. PMID: 37188699 Free PMC article.
Transplantation for amyloidosis.
Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Gertz MA, et al. Among authors: hayman sr. Curr Opin Oncol. 2007 Mar;19(2):136-41. doi: 10.1097/CCO.0b013e32801494c6. Curr Opin Oncol. 2007. PMID: 17272986 Review.
Amyloidosis: diagnosis and management.
Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Gertz MA, et al. Among authors: hayman sr. Clin Lymphoma Myeloma. 2005 Nov;6(3):208-19. doi: 10.3816/CLM.2005.n.048. Clin Lymphoma Myeloma. 2005. PMID: 16354326 Review.
VEGF inhibition, hypertension, and renal toxicity.
Hayman SR, Leung N, Grande JP, Garovic VD. Hayman SR, et al. Curr Oncol Rep. 2012 Aug;14(4):285-94. doi: 10.1007/s11912-012-0242-z. Curr Oncol Rep. 2012. PMID: 22544560 Free PMC article. Review.
Coagulation Abnormalities in Light Chain Amyloidosis.
Abdallah N, Muchtar E, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Pruthi RK, Gertz MA, Kumar SK. Abdallah N, et al. Among authors: hayman sr. Mayo Clin Proc. 2021 Feb;96(2):377-387. doi: 10.1016/j.mayocp.2020.06.061. Mayo Clin Proc. 2021. PMID: 33549257
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, Dispenzieri A, Dingli D, Fonder A, Gertz MA, Gonsalves W, Hayman SR, Hwa Y, Hobbs M, Kourelis T, Lacy MQ, Leung N, Muchtar E, Warsame R, Jevremovic D, Kyle RA, Rajkumar SV, Kumar S. Zanwar S, et al. Among authors: hayman sr. Am J Hematol. 2023 Oct;98(10):1540-1549. doi: 10.1002/ajh.27023. Epub 2023 Jul 8. Am J Hematol. 2023. PMID: 37421603
IgM amyloidosis: clinical features in therapeutic outcomes.
Gertz MA, Buadi FK, Hayman SR. Gertz MA, et al. Among authors: hayman sr. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):146-8. doi: 10.3816/CLML.2011.n.034. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454218 Review.
320 results